Armatus Bio, a late-preclinical stage biotech innovator developing vectorized RNAi medicines in neuromuscular disorders, today announced the publication of foundational data in Molecular Therapy ...

Vectorized antibodies hold promise to overcome many of these limitations and provide a great opportunity for DNA and RNA technology companies to enter larger markets compared with the rare disease ...

Please provide your email address to receive an email when new articles are posted on . VTx-002 targets proteins that play a significant role in neurodegenerative disease. Enrollment in and ...

A year after AbbVie and Voyager Therapeutics teamed up on Alzheimer’s disease, they are expanding their partnership to include Parkinson’s disease and other diseases in which misfolded alpha-synuclein ...